• ViMove+ product showing 15x higher growth rates than historical in the US Physical Therapy market
• Clinics delivering consistent annual recurring revenue of ~$3,000 AUD per clinic
• Arizona training day achieved 90% conversion, validating rollout strategy

dorsaVi Ltd (ASX:DVL) is pleased to announce that its ViMove+ product has shown phenomenal early growth trajectory in the US Physical Therapy (PT) market, with growth rates already tracking 15 times higher than historical monthly acquisition trends. Clinics are delivering consistent annual recurring revenue (ARR) of ~$3,000 AUD per clinic. The US PT market remains large and relatively unpenetrated for objective movement analysis products, with over 66,000 PT clinics nationwide. Drawing on years of on-the-ground learning, dorsaVi has developed a repeatable, state-by-state roll-out strategy that is now delivering tangible growth. This includes prioritizing franchise groups, conducting face-to-face training days to drive conversion, and activating a surgeon referral flywheel. The US sports medicine community is increasingly recognizing the importance of objective data in Return to Play (RTP) decisions, with over 60 US surgeons now prescribing dorsaVi's Athletic Movement Index (AMI) test. Surgeon-led pathways are driving adoption by driving PT clinic uptake, richer economics, and compressing the sales cycle. dorsaVi maintains a differentiated position through clinically validated sensor technology, FDA clearance, and surgeon endorsement, while continuing to refine its products and expand its geographic reach and clinical partnerships.

Looking forward, dorsaVi is focused on expanding its geographic reach in the US, strengthening clinical partnerships, continuing to refine its ViMove+ and AMI products, and exploring strategic commercial partnerships to accelerate adoption.